Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCRIII, in healthy volunteers

Vox Sanguinis, 05/11/2012

Roledumab is safe and well tolerated in healthy RhD–negative volunteers and shows a pharmacokinetic profile similar to that of polyclonal anti–RhD immunoglobulin.

Print Article Summary Cat 2 CME Report